-+ 0.00%
-+ 0.00%
-+ 0.00%

Tvardi publishes new preclinical ulcerative colitis data for STAT3 inhibitor TTI-101 in Int J Mol Sci

PUBT·09/24/2026 12:00:38
Listen to the news
Tvardi publishes new preclinical ulcerative colitis data for STAT3 inhibitor TTI-101 in Int J Mol Sci
  • Tvardi Therapeutics disclosed newly published preclinical ulcerative colitis data supporting its STAT3 inhibitor program.
  • Results have already been presented via journal publication, not a future conference readout.
  • The study showed the oral drug concentrated in the colon and broadly reduced disease biology linked to inflammation and abnormal tissue growth.
  • Findings strengthen the rationale to advance TTI-109, a next-generation STAT3 inhibitor, toward ulcerative colitis development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240800PRIMZONEFULLFEED9833097) on September 24, 2026, and is solely responsible for the information contained therein.